Skip to content

Sarepta Therapeutics, Inc.

SRPT· NasdaqCore metricsCIK 873303
Last sale
Nov 12, 2026 · -3.90%
Market cap
$1.72B
107.24M shares
Filings
1,021
$323.76M
Q3 2026+15.6% FY25 yoy
-$28.46M
Q3 2026N/M FY25 yoy
-$9.04M
Q3 2026N/M FY25 yoy
$48.78M
Q3 2026derivedN/M FY25 yoy
-$0.27
Q3 2026N/M FY25 yoy
$472.76M
Q3 2026−27.4% FY25 yoy
$1.72B
—
1.2×
1.1×
10.27%
—

Twelve months to Sep 30, 2026 · derived

Price

$16.0111.06%$1.99past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$2.20BFY 2025
$2.20B0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$2,198,237,000reported
FY 20242024-12-31$1,901,979,000reported
FY 20232023-12-31$1,243,336,000reported
FY 20222022-12-31$843,769,000reported
FY 20212021-12-31$612,401,000reported
FY 20202020-12-31$455,865,000reported
FY 20192019-12-31$380,833,000reported
FY 20182018-12-31$301,034,000reported
FY 20172017-12-31$154,584,000reported
FY 20162016-12-31$5,421,000reported
FY 20152015-12-31$1,253,000reported
FY 20142014-12-31$9,757,000reported

Capital returns

Dividends and buybacks · FY2023 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$25.01M$25.01M—104.99M sh+8.2%—
FY2024—$0.00$0.00—97.03M sh+3.4%—
FY2023—$0.00$0.00—93.86M sh+6.7%—

Segments

Revenue by Geography, FY2022 to FY2022FY2022US · FY2022 · $747.10MOutside of U.S. · FY2022 · $96.70M
LineFY2022ShareChange
US$747.10M80%—
Outside of U.S.$96.70M10%—
Total$933.01M

From the 10-K filed Feb 28, 2023SRPT

Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR